|[February 21, 2014]
IntegraGen Announces Publication of Study Which Supports the Association of Common Genetic Variants in the Development of Autism
CAMBRIDGE, Mass. --(Business Wire)--
IntegraGen, a leading player in the development and marketing of
molecular diagnostic testing in autism and oncology, today announced
that Frontiers in Genetics has published the results
of a study that reports on the association of common
genetic variants with autism spectrum disorder (ASD). The study, entitled
"A scoring strategy combining statistics and functional genomics
supports a possible role for common polygenic variation in autism"
details the use of a combined approach using genome-wide association
studies and functional genomics to develop a gender-based genetic
scoring model based on common variants identified as being associated
The research, which was based on results obtained from genome-wide
association studies utilizing data from the Autism Genetic Resource
Exchange (AGRE) and a separate independent replication sample, included
nearly 2,000 individuals diagnosed with autism and 600 unaffected
siblings. The results of the study identified the role of common
variants, also known as single-nucleotide polymorphisms (SNPs), in
multiplex autism families. The study was a result of a collaborative
research effort between investigators at IntegraGen and external experts
in the field of autism.
"Delays in the�identification of children at risk of autism
limit the opportunity for early assessment and the potential diagnosis
of autism spectrum disorder and associated access to early behavioral
intervention which have been shown to significantly improe IQ scores,
language and social skills.�This study supports the use of
a�gender-based genetic scoring model, based on common variants, to
earlier identify children at increased risk of autism"�commented David
Cohen, M.D., Ph.D.,�Department of Child and Adolescent Psychiatry,
Assistance Publique-H�pitaux de Paris (AP-HP)�and co-author the study.
"The results of this study builds on data IntegraGen has previously
published that identified gender-specific single-nucleotide
polymorphisms which predict the risk of autism in children who have an
older sibling diagnosed with ASD," stated Bernard Courtieu, IntegraGen's
President and CEO. "These findings contribute to the scientific evidence
supporting the clinical utility of the ARISk
Test towards identifying children who are at increased risk of
autism, leading to an earlier diagnosis, earlier intervention, and
The Centers for Disease Control (CDC) has reported that autism spectrum
disorder affects 1 in 88 children in the United States with the
prevalence being five times higher in boys than girls. The CDC also
reports that, on average, children do not receive an ASD diagnosis until
they are more than 4 years of age.
ABOUT THE ARISK® TEST:
Test is a genetic test that analyzes the likelihood that a child
will develop autism. IntegraGen has recently launched the ARISk2 Test
which expands the clinical utility of the test to now include children
who have signs of developmental delay or autism in addition to children
who have an older sibling diagnosed with an autism spectrum disorder.
The ARISk Test is a laboratory developed test that is only available
through licensed medical practitioners. DNA samples are collected via a
simple cheek swab and sent to a CLIA-certified laboratory where the
genetic markers are detected via state-of-the-art genomic testing
instruments. It is recommended that children who are identified as
having a higher risk of autism be referred to an autism specialists for
a diagnostic work-up and, if diagnosed, early behavioral intervention.
Founded in 2000, IntegraGen (ALINT.PA) is a biotechnology company
focused on the development and commercialization of molecular diagnostic
tests in the fields of autism and oncology. IntegraGen's mission is to
translate molecular research into clinical practice through the
identification of novel genetic biomarkers and the subsequent
development of molecular diagnostic tests which allow clinicians to
better manage the clinical care of their patients. IntegraGen is also a
leader in delivering expert genomic service solutions to academic
researchers and life sciences companies as a result of its scientific
knowledge and technological expertise related to cutting edge genomic
platforms and bioinformatics.
For more information about the ARISk Test visit www.arisktest.com.
For more information on IntegraGen visit www.integragen.com.
[ InfoTech Spotlight's Homepage ]